Glass House Brands (GLAS) EBT Margin (2020 - 2026)

Glass House Brands (GLAS) posted quarterly EBT Margin of 34.43% for Q1 2026, down 6.72% quarter-over-quarter from 32.26% in Q4 2025.

Glass House Brands (GLAS) EBT Margin (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported EBT Margin for 7 consecutive years, with 34.43% the latest figure, recorded in Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 34.43%; the TTM figure through Mar 2026 stood at 13.44% (changed N/A YoY), while the FY2025 annual figure was 9.35%, down 1494.0% from the prior year.
EBT Margin retreated to 34.43% in Q1 2026 per GLAS's latest filing, from 32.26% in the prior quarter.
Across five years, EBT Margin topped out at 62.99% in Q3 2022 and bottomed at 75635543.01% in Q2 2022.
Historically, EBT Margin has averaged 11965098.17% across 5 years, with a median of 33.34% in 2025.
Annual changes were most pronounced in 2022 — EBT Margin plunged 2000000000 bps — and 2024, when it jumped 2000000000 bps.
Glass House Brands' EBT Margin stood at 71.86% in 2022, then tumbled by 61249603 bps to 44015219.97% in 2023, then jumped by 100 bps to 18.99% in 2024, then plunged by 270 bps to 32.26% in 2025, then dropped by 7 bps to 34.43% in 2026.
Business Quant data shows GLAS's EBT Margin at 34.43% in Q1 2026, 32.26% in Q4 2025, and 28.92% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-10.99%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	47.58%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Glass House Brands	830.21 Mn	811.66 Mn	15.77 Mn	-3.21%

Download Data